Mirion Technologies (MIR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
11 Feb, 2026Executive summary
Achieved record orders exceeding $1 billion in 2025, driven by strong nuclear power and nuclear medicine markets, with double-digit organic growth in both segments.
Completed acquisitions of Certrec and Paragon Energy Solutions, increasing nuclear power revenue exposure to as much as 47% and broadening North American reach.
Large opportunity pipeline for 2026 exceeds $400 million, with significant SMR and new build projects.
Integration of acquisitions expected to drive commercial synergies, global expansion, and full-year contributions in 2026.
Strategic focus on AI and digital transformation, with 17 internal AI applications launched and a new Chief AI and Digital Officer appointed.
Financial highlights
2025 revenue grew 7.5% year-over-year to $925.4 million, with organic growth of 3.9%.
Adjusted EBITDA rose 12% to $227.9 million (24.6% margin), with Q4 adjusted EBITDA at $77.6 million (28.0% margin).
Adjusted EPS was $0.46, up from $0.41 in 2024, despite a 50 million share increase from convertible notes and equity raise.
Adjusted free cash flow doubled to $131 million, representing a 57% conversion of Adjusted EBITDA.
GAAP net income for 2025 was $28.8 million, reversing a loss of $36.1 million in 2024.
Outlook and guidance
2026 revenue expected to grow 22%-24%, with organic growth guidance of 5%-7%.
Adjusted EBITDA guidance for 2026 is $285-$300 million, with margins of 25%-26%.
Adjusted free cash flow projected at $155-$175 million for 2026, with 54%-58% conversion.
Adjusted EPS guidance for 2026 is $0.50-$0.57, now including stock-based compensation.
Q1 2026 expected to be the lightest quarter for revenue and EBITDA, with margin expansion resuming in the back half.
Latest events from Mirion Technologies
- Q3 2025 saw strong revenue, profit, and cash flow growth, with major nuclear wins and financings.MIR
Q3 202517 Mar 2026 - Nuclear and AI tailwinds fuel growth, margin expansion, and global market leadership.MIR
Citi's Global Industrial Tech & Mobility Conference 202618 Feb 2026 - Guidance raised to 6–8% organic growth and ~30% EBITDA margin by 2028, led by nuclear and medical momentum.MIR
Investor Day 20243 Feb 2026 - Q2 revenue up 5%, adjusted EBITDA up 10.2%, and guidance raised on strong segment growth.MIR
Q2 20242 Feb 2026 - Q1 2024 organic revenue up 5.5% as innovation and ESG drive growth in key markets.MIR
Jefferies Global Healthcare Conference1 Feb 2026 - Q3 revenue up 8.2%, margin expands, and 2024 guidance raised with improved leverage.MIR
Q3 202417 Jan 2026 - Strong growth driven by nuclear tailwinds, recurring revenue, and expanding medical opportunities.MIR
Goldman Sachs Industrials and Materials Conference11 Jan 2026 - Record 2024 results, margin expansion, and strong 2025 outlook driven by nuclear and medical growth.MIR
Q4 202429 Dec 2025 - Q1 2025 delivered revenue, margin, and order growth, with guidance raised despite tariff headwinds.MIR
Q1 202524 Dec 2025